Valvular & structural heart disease
Transcatheter aortic valve implantation in patients with extra-small aortic annuli
Authors' conclusion
TAVI is a safe and feasible treatment in patients with extra-SAA with a high rate of technical success. The use of SEV was associated with a lower rate of intraprocedural complications, higher device success at 30 days and better haemodynamic outcomes compared to BEV.
Study context
- Population
- Patients with extra-small aortic annuli (annulus area <280 mm² and/or perimeter <60 mm) undergoing transcatheter aortic valve implantation (TAVI)139 (92.7%) women
- Participants
- 150 patients
- Exposure
- SEV vs BEV in TAVI
- SEVn = 110
- Outcome
- Primary efficacy endpoint: device success; primary safety endpoint: early safety (VARC-3 criteria)
- Follow-up
- 30 days
Main finding
As reported in the abstract
Device success
P = 0.032
- Overall 30-day device success
- 81.3%
Observational data: associations, not effects.
Further findings
Intraprocedural technical success
P = 0.001
Severe PPM
P = 0.039
- Intraprocedural technical success — Overall technical success
- 91.3%
- Severe prosthesis-patient mismatch (PPM) — Overall severe PPM
- 12%
Severe PPM
- No impact of severe PPM on all-cause mortality, CV mortality or HF readmission at 2 years
Safety
- Primary safety endpoint (early safety, VARC-3) · 30 days — Primary safety endpoint occurred (overall) · no difference between groups
- 72.0% · P = 0.118
Original publication
Transcatheter aortic valve implantation in patients with extra-small aortic annuli. EuroIntervention. Published 17 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →